logo-loader
viewEnvisagenics

Envisagenics using SpliceCore platform and A.I. to find hidden cures faster

Envisagenics, Inc CEO Maria Luisa Pineda sat down with Proactive’s Christine Corrado at BIO CEO in New York. The New York-based biotechnology company is leveraging artificial intelligence and RNA-splicing analytics for discovery and development of disease-specific therapeutics. The privately-held company was recently awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

17 hours, 34 minutes ago

2 min read